DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Investigation of the Pharmacokinetic Properties of Biphasic Insulin Aspart 50 in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 50

First Posted Date: 2010-11-17

Last Posted Date: 2015-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01242826

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543

Phase 1

Completed

Conditions: Haemophilia A
Congenital Bleeding Disorder

Interventions: Drug: turoctocog alfa

First Posted Date: 2010-11-10

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01238367

Locations: 🇯🇵
Novo Nordisk Investigational Site, Suginami-ku, Tokyo, Japan

Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia B
Haemophilia A

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2010-11-04

Last Posted Date: 2014-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT01234545

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin detemir
Dietary Supplement: Dietary regimen

First Posted Date: 2010-11-02

Last Posted Date: 2017-05-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 611

Registration Number: NCT01232491

Locations: 🇹🇷
Novo Nordisk Investigational Site, Samsun, Turkey

Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency

Phase 3

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency

Interventions: Drug: catridecacog

First Posted Date: 2010-10-28

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 6

Registration Number: NCT01230021

Locations: 🇬🇧
Novo Nordisk Investigational Site, Reading, United Kingdom

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A
Haemophilia B
Healthy

Interventions: Drug: NNC 0172-0000-2021
Drug: placebo

First Posted Date: 2010-10-26

Last Posted Date: 2019-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 52

Registration Number: NCT01228669

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2010-10-22

Last Posted Date: 2017-02-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3152

Registration Number: NCT01226966

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC 0151-0000-0000

First Posted Date: 2010-10-19

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT01223911

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B

Completed

Conditions: Haemophilia A
Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2010-10-13

Last Posted Date: 2015-04-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01220141

Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2010-10-06

Last Posted Date: 2014-10-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 245

Registration Number: NCT01215435

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy